Follow the 메디톡스 share price and the full management transaction log of the company, a listed equity based in South Korea. Shares trade on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 메디톡스 has recorded 80 public disclosures. Market capitalisation: €468bn. The latest transaction was filed on 2 April 2026 (Purchase). Among the most active insiders: 정현호. Every trade is free.
78
Insider Decl.
n/a
Thresholds
n/a
37 ops.
Buy Volume
n/a
3 ops.
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 14,840 of 28,065 companies
50.4
score / 100
Value
47
Quality
54
FCF yld5.3%
Earn yld3.2%
EV/EBITDA21.7x
ROE4.8%
Gross mgn58%
Net mgn6.7%
Debt/EBITDA2.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Medytox is a company specializing in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on the development of biopharmaceutical products.